Tempest Therapeutics, Inc.
TPST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001544227
No open-market purchases or sales by Tempest Therapeutics, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.44M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Tempest Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 22 | 21 | −1 |
| Shares | 786.9K | 1.29M | +507.4K (+64.5%) |
| Value | $1.29M | $1.44M | +$146.2K (+11.3%) |
New holders (4)
Institutions that held Tempest Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Squarepoint Ops LLC | 30,900 | $34.3K | 0.00% |
| Citadel Advisors LLC | 19,820 | $22.0K | 0.00% |
| Barclays PLC | 222 | $246 | 0.00% |
| Caitong International Asset Management Co., Ltd | 3 | $3 | 0.00% |
Sold out (5)
Institutions that held Tempest Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| FMR LLC | 33,225 | $54.5K |
| Dimensional Fund Advisors LP | 11,444 | $18.8K |
| Vanguard Global Advisers, LLC | 168 | $276 |
| Citigroup Inc | 8 | $13 |
| JPMorgan Chase & Co | 5 | $8 |